洞察慢性淋巴细胞白血病的遗传异常和信号通路相互作用:从致病源到治疗策略
Anna Sobczyńska-Konefał1,2, Monika Jasek1, Lidia Karabon1
1L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolf Weigl 12, 53-114, Wroclaw, Poland.
Biomarker research
|December 29, 2024
概括
向疗法改善了慢性淋巴细胞白血病 (CLL) 治疗,但耐药性仍然存在. 了解B细胞受体 (BCR) 信号和适应性抵抗机制对于开发个性化的CLL疗法至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是一种常见的成人白血病,以成熟的B细胞积累为标志.
- 像BTK抑制剂和Bcl-2抑制剂这样的向疗法在疗效方面已经超过了化疗免疫疗法.
- 尽管治疗取得了进展,但由于CLL异质性和适应性耐药性,疾病复发仍然是一个挑战.
研究的目的:
- 审查推动CLL存活,扩散和治疗耐药性的分子机制.
- 阐明BCR信号传导,NF-κB,PI3K/AKT和ROR1通路在CLL中的作用.
- 突出CLL中的遗传和通路适应性耐药机制.
主要方法:
- 对CLL中的分子途径和抵抗机制的文献综述.
- 分析B细胞受体 (BCR) 信号在CLL进展中的作用.
- 综合目前关于CLL针对性治疗耐药性的知识.
主要成果:
- BCR信号传递,NF-κB,PI3K/AKT和ROR1通路是CLL细胞存活和抵抗的关键.
- 遗传突变和适应性路径耐药性导致CLL治疗失败.
- BCR信号被确定为CLL进展的关键驱动因素.
结论:
- 需要进一步的研究来了解CLL的起源和遗传因素的相互作用.
- 建议基于分子分析的个性化治疗策略.
- 解开BCR信号通路的复杂相互作用对于改善CLL患者的治疗结果至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K
The Intrinsic Apoptotic Pathway
5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K


